Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Acasti Completes IND Submission - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Acasti Completes IND Submission

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Acasti Pharma, Laval, Québec, Canada, a subsidiary of Neptune Technologies & Bioressources Inc., has submitted an Investigational New Drug (IND) application to the U.S. FDA to initiate a Pharmacokinetic (PK) trial of CaPre in the U.S.

The proposed PK trial is the first step in the Corporation’s U.S. clinical strategy to initiate PK and Phase III trials of CaPre in the U.S. It is an open-label, randomized, multiple-dose, single-center, parallel-design study that will evaluate blood profiles and bioavailability of omega-3 phospholipids on healthy volunteers taking single and multiple daily oral doses of 1, 2 and 4 grams of CaPre.   

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters